Combining DR5 Agonist and PD-1 Antagonist to Overcome Tumor Immune Evasion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in effectively inhibiting tumor growth due to immune evasion mechanisms mediated by PD-1 and its ligands, which hinder the activation of T cells and induce apoptosis in tumor cells, limiting the efficacy of existing anticancer regimens.
Innovation Solution
The co-administration of a DR5 agonist and a PD-1 antagonist, such as specific antibodies or ligands, to synergistically inhibit tumor growth by enhancing apoptosis in cancer cells while blocking immune evasion pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a PD-1 antagonist is used to block immune evasion pathways, then T cell activation is enhanced, but tumor growth inhibition is limited due to insufficient apoptosis induction
Solution Approach 1:
The patent combines a PD-1 antagonist (to block immune evasion and enhance T cell activation) with a DR5 agonist (to directly induce apoptosis in tumor cells). This merging of two different mechanisms—immune modulation and direct cytotoxicity—addresses the limitation of using PD-1 antagonists alone, which enhance T cell activation but are insufficient for robust tumor growth inhibition.
2Productivity
If a DR5 agonist is used to induce apoptosis in tumor cells, then tumor cell death is increased, but immune evasion mediated by PD-1 pathways remains unaddressed
Solution Approach 1:
The combination therapy merges the direct apoptosis-inducing effect of DR5 agonists with the immune modulation effect of PD-1 antagonists. While the DR5 agonist drives tumor cell death, the PD-1 antagonist simultaneously blocks immune evasion pathways, ensuring that the tumor microenvironment remains immunologically hostile to residual cancer cells.
3Ease of operation
If existing anticancer regimens are used, then treatment is administered, but efficacy is limited due to the dual mechanisms of tumor survival through immune evasion and apoptosis resistance
Solution Approach 1:
The patent merges two therapeutic agents with complementary mechanisms of action into a single treatment regimen. The PD-1 antagonist and DR5 agonist are administered together (either simultaneously or sequentially) to overcome the dual survival mechanisms of tumors—immune evasion and apoptosis resistance—thereby significantly improving anticancer efficacy while maintaining ease of operation through standardized administration protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy significantly reduces tumor volume and inhibits growth, achieving a synergistic effect that surpasses the efficacy of either treatment alone, with potential applications in various types of cancer by enhancing anti-tumor immune responses.
Implementation Method 1
DR4 and DR5 recruit FAS associated protein with death domain (FADD) and caspase-8 to form the death-inducing signaling complex (DISC), which activates caspase-8, subsequently leading to the activation of executioner caspases such as caspase-3 that induce apoptosis
Implementation Method 2
Programmed Cell Death 1 (PD-1) is a cell surface signaling receptor that plays a critical role in the regulation of T cell activation and tolerance... binding of ligand to PD-1 results in immune evasion. In addition, blockade of this interaction results in anti-tumor activity.
Data Source
AI summary
Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist in combination with a DR4 or DR5 agonist.